This study is a large, prospective, pragmatic, controlled comparison of patient-centric outcomes [quality of life (QOL), toxicity, and disease control] between parallel cohorts of men with prostate...
Current Studies
Clinical trials advance medical treatment and therapy to increase survival and quality of life.
Research improves the standard of care as we develop protocols to improve the prevention, diagnosis, treatment and rehabilitation of health conditions throughout the body.
Successful treatments we know today are the result of past clinical trials.
- Cardiology (1)
- COVID-19 (1)
- Gastroenterology (1)
- Genetics (1)
- Hematology (1)
- Neurovascular (1)
- Oncology/Cancer (20)
- Orthopedics (1)
- Pain Management (2)
- Pediatric Gastroenterology (1)
- Pulmonary (4)
- Radiation Therapy (10)
- Rheumatology (1)
- Urology (5)
- Bladder Cancer (1)
- Breast Cancer (1)
- Cancer (10)
- Cancer Screening (2)
- Chronic Pain (2)
- COVID-19 (1)
- Erectile Dysfunction (1)
- Erosive Esophagitis (1)
- Hepatocellular Carcinoma (2)
- Ischemic Stroke (1)
- Leukemia (1)
- Lupus (SLE) (1)
- Male Overactive Bladder (1)
- Metastatic Colorectal Cancer (2)
- Multiple Myeloma (1)
- Non-Small Cell Lung Cancer (1)
- Oropharyngeal Cancer (2)
- Osteoarthritis (1)
- Prostate Cancer (4)
- Prostatectomy (1)
- Radiation Therapy (3)
- Ulcerative Colitis (1)
- Urinary Urge Incontinence (UUI) (2)
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free ...
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
...Prospective, Multicenter, Single-Arm Study of Vanquish™ Water Vapor Ablation for Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermedia...





